Loading asset research
Black Diamond Therapeutics Inc. Common Stock
BDTXNasdaq · USD · StocksQuote as of · Exchange session not verified$1.98
+1.02%
Today
BDTX
Loading 1D prices…
Market cap
$113.5M
Volume
589.1K
52w high
$4.9452w low
$1.60Company profile
Black Diamond Therapeutics Inc. Common Stock
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Cambridge, MA, United States
Employees
21
Fiscal year end
1231
CIK
1701541
Session & valuation
Open$1.99
Previous close$1.96
Day high$2.00
Day low$1.94
30-day avg. volume572K
Outstanding shares57.5M
Diluted EPS$0.39
Latest annual period
P/E (trailing)5.08
P/E (forward)-1.98
Price / book1.18
Beta3.31
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ENGNenGene Therapeutics Inc. Common Stock | $120.6M | $0.00 | — | -$1.34 | +1.98% | Hold |
| CRBUCaribou Biosciences Inc. Common Stock | $136.2M | $11.2M | -1327.40% | -$1.59 | -6.57% | Buy |
| ATRAAtara Biotherapeutics Inc. Common Stock | $94.2M | $120.8M | +27.07% | $2.57 | -5.16% | Buy |
| CRDFCardiff Oncology Inc. Common Stock | $94.1M | $593K | -7.73% | -$0.69 | +0.41% | Hold |
| CGTXCognition Therapeutics Inc. Common Stock | $93.5M | $0.00 | — | -$0.32 | +0.31% | Buy |